Latest news with #BCDA
Business Insider
10-07-2025
- Business
- Business Insider
BioCardia files to sell 549K shares of common stock for holders
17:22 EDT BioCardia (BCDA) files to sell 549K shares of common stock for holders Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
GMA Network
03-07-2025
- Business
- GMA Network
Camp John Hay to roll out EV shuttle service by July 15
Visitors of the Camp John Hay in Baguio City will be given free rides during the six-month trial period of its electric vehicle shuttle service that will loop around designated stations around the former US base, targeted to start on July 15. The pilot run of the 'John Hay Loop' will involve an initial three units of electric vehicles, with pre-determined routes and schedules yet to be finalized. The service will be done in partnership with the Bases Conversion and Development Authority (BCDA) and its subsidiary John Hay Management Corp. and South Korea-based DeviceDesign Co. Ltd. and Cordillera Basic Sector Transport Cooperative (CBSTC). 'Through this project, the BCDA seeks to show its commitment to help Baguio City and the community in addressing emerging urban problems, while also fulfilling our promise to take care of the environment and Baguio's natural charm and beauty,' BCDA president and chief executive officer Joshua Bingcang said in a statement. Under a memorandum of understanding (MOU), DeviceDesign and CBSTC will evaluate commuter experience and assess logistical and operational constraints of the service through ridership monitoring and operational data gathering, and will then provide recommendations and design inputs for the long-term implementation of John Hay Loop. 'We believe that if we have an efficient and effective public transportation system, that [will stimulate] the economy of a place, and we share this vision with the BCDA,' CBSTC chief executive officer Jude Wal said. The BCDA took control of Camp John Hay in January, after the Baguio Regional Trial Court in an order dated January 3, 2025 upheld the Supreme Court ruling and junked Camp John Hay Development Corp.'s (CJH DevCo) appeal to prevent the full return of the property. The BCDA in March said it received P1 billion in investments from lease agreements in Camp John Hay. It earlier said it is looking to hit P10 billion worth of investments following the takeover, as it plans to offer 70 hectares of untapped land in the area to the private sector. —VAL, GMA Integrated
GMA Network
29-06-2025
- Business
- GMA Network
P360-million dorm for student-athletes to be built in New Clark City
The five-storey dormitory will be built at the National Academy of Sports (NAS) in New Clark City, Capas, Tarlac. Photo: Bases Conversion and Development Authority The Bases Conversion and Development Authority (BCDA) is set to start the construction of a P360-million dormitory that will house up to 400 student-athletes at the National Academy of Sports (NAS) in New Clark City, Capas, Tarlac. According to the BCDA, the dormitory will be a five-storey building with its 1,500 square meters to include 14 quad-sharing rooms for female students, and another 14 quad-sharing rooms for males. It will be constructed in partnership with the Department of Budget and Management (DBM). The facility will also house an atrium, a dining hall, recreational spaces, a kitchen and dishwashing area, administrative offices, and laundry and utility rooms. 'By equipping our young athletes with world-class resources and facilities, we are not only developing champions in sports—we are nurturing the future leaders of our country,' BCDA president and chief executive officer Joshua Bingcang said. Established under Republic Act 11470, the NAS is dedicated to nurturing the athletic skills of Filipino student-athletes, as it seeks to provide world-class facilities at par with international standards, and opportunities to compete internationally. The NAS currently houses 270 student-athletes enrolled in academic and athletic disciplines, with a new gymnasium and dedicated gymnastics court also being constructed. 'Our student-athletes deserve nothing less than a world-class environment where they can train harder, dream bigger, and shine brighter,' DBM Secretary Amenah Pangandaman said. Under its mandate, the BCDA is tasked to help strengthen the Armed Forces of the Philippines (AFP), while building cities. It also engaged in public-private partnerships to boost public infrastructure such as tollways, airports, seaports, and major real estate developments. — BM, GMA Integrated News
GMA Network
23-06-2025
- Business
- GMA Network
SCTEX Interchange eyed in Hermosa, Bataan — BCDA
The government is looking to collaborate with the NLEX Corp. to put up a road interchange linking Hermosa, Bataan to the Subic-Clark-Tarlac Expressway (SCTEX), the Bases Conversion and Development Authority (BCDA) said Monday. According to the BCDA, the interchange will be a joint collaboration with the Department of Public Works and Highways (DPWH), NLEX Corp., and the local government of Hermosa, as part of the long-term development strategy to boost regional connectivity along the SCTEX. 'More than just an infrastructure, this interchange will unlock a new gateway to economic opportunities for Central Luzon — providing much-needed support for the region's growing logistics and manufacturing sectors, and generating more jobs for Filipinos,' BCDA president and chief executive officer Joshua Bingcang said in an emailed statement. 'In support of the Luzon Economic Corridor initiative, the enhancement of SCTEX will drive industrial growth and strengthen the region's role as a key engine of national progress,' he added. The SCTEX — a 94.62-kilometer expressway connecting Tipo, Subic and La Paz, Tarlac — involves a 35-year concession agreement between the BCDA and the Pangilinan-led NLEX Corp. Under the current agreement, each party receives 50% of the revenues. Aside from the SCTEX, NLEX Corp. also operates the North Luzon Expressway (NLEX), the Manila-Cavite Toll Expressway (CAVITEX), the Cavite-Laguna Expressway (CALAX), and the Cebu-Cordova Link Expressway (CCLEX), and the NLEX Connector. — RSJ, GMA Integrated News
Yahoo
15-05-2025
- Business
- Yahoo
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BioCardia Inc (NASDAQ:BCDA) reported positive safety and meaningful benefits from their cardiac cell therapy for heart failure patients, addressing a significant unmet clinical need. The company is actively engaging with the FDA and Japan's PMDA to align on pathways for making their therapy available, indicating progress towards regulatory approval. BioCardia Inc (NASDAQ:BCDA) is enrolling patients in the Cardiac Heart Failure 2 trial, which aims to confirm previous results and enhance enrollment. The Helix biotherapeutic delivery system is being prepared for submission for approval, potentially becoming the first approved transendocardial biotherapeutic delivery system in the U.S. BioCardia Inc (NASDAQ:BCDA) has a strong focus on partnerships, which could create meaningful value for shareholders across their four platforms: CardiAM, Cardiello, Helix, and Morph DNA. Total expenses increased by $396,000 quarter over quarter, driven primarily by research and development costs. The company reported a net loss of $2.7 million in Q1 2025, up from $2.3 million in Q1 2024. Cash and cash equivalents were low at $949,000 at the end of the quarter, necessitating a small financing to support ongoing operations. The Cardiac Heart Failure trial did not hit its primary endpoint, introducing significant risks to the approval pathway. BioCardia Inc (NASDAQ:BCDA) faces challenges in the lengthy and uncertain process of deal discussions and partnerships, which can take a long time to finalize. Warning! GuruFocus has detected 7 Warning Signs with BCDA. Q: Can you discuss the levels of maturity in your business development deals and any ongoing discussions? A: Peter Altman, CEO: We have several active discussions with large-cap strategics, particularly around our Morph Axis pro product family, which is already approved and in use. The cardiac electrophysiology market is growing rapidly, and our technology can help access this market. On the Helix side, we are in talks with potential partners for biotherapeutic delivery. Our Cardialo cell therapy has demonstrated safety, and we are open to partnerships for other clinical indications. For Cardiam, we are focused on the approval process in Japan and have ongoing discussions with potential distributors. Q: How does the potential approval process in Japan compare to the FDA's BLA acceptance, and what is its significance? A: Peter Altman, CEO: The process in Japan is similar to the FDA's BLA acceptance. Japan's PMDA is rigorous, and we expect clarity on approval submission within six months. Approval would provide clarity for distribution partners and help us prepare for commercial launch. Our extensive clinical data and minimally invasive delivery method position us favorably compared to peers in Japan. Q: Can you explain the strategy behind running the confirmatory trial while also submitting to the FDA for approval? A: Peter Altman, CEO: We believe in our therapy and are continuously developing evidence. Although our previous trial did not hit its primary endpoint, we are advancing with a second trial, which is reimbursed by Medicare, reducing costs. The new trial focuses on the greatest responders and includes improvements like using our new Morph DNA platform and a revised endpoint to enhance trial power. Q: Does the recent "most favored nation" pricing policy or tariffs impact your business? A: Peter Altman, CEO: Currently, the "most favored nation" policy does not impact us as we are not selling Cardiam outside the U.S. We aim to benchmark international pricing based on U.S. reimbursement. Tariffs are complex, but most of our manufacturing is U.S.-based, minimizing impact. We price based on value, and our margins remain strong even at competitive pricing. Q: What are the financial highlights for the first quarter of 2025? A: David McClung, CFO: Total expenses increased to $2.7 million, driven by R&D expenses related to cardiac heart failure trials. SG&A expenses were stable at $1.2 million. Net loss was $2.7 million, with cash and equivalents at $949,000 before additional financing. We continue to manage capital carefully. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
